Increase of lipoprotein (a) with troglitazone

Lancet

Volumn 350, Issue 9093, 1997, Pages 1748-1749

  Matsumoto, Kazunari ^a   Miyake, Seibei ^a   Yano, Mayumi ^a   Ueki, Yukitaka ^a   Tominaga, Yuko ^a  

^a Sasebo Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA; TROGLITAZONE;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0031581509     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63572-6     Document Type: Article

References (5)

1. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39: 701-09.
2. Petrie J, Small M, Connell J. "Glitazones", a prospect for non-insulin-dependent diabetes. Lancet 1997; 349: 70-71.
3. Schaeffer EJ, Fava SL, Jenner JL, et al. Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999-1003.
4. Borona E, Moghetti P, Zancanaro C, et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 1989; 68: 374-78.
5. Chapman MJ, Huby T, Nigon F, Thillet L. Lipoprotein (a) implication in atherosclerosis. Atherosclerosis 1994; 110: S69-75.